Answer
Yes, mavacamten is contraindicated during concomitant treatment with the combination of a strong CYP2C19 inhibitor and a strong CYP3A4 inhibitor.
Sources for this answer
- Mavacamten BMS 2.5 mg, 5 mg, 10 mg, 15 mg hard capsulesBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.3 Contraindications · Version 6Document updated
Sources checked